MANKIND.NS Balance Sheet
Mankind Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:37
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹25.24 Bn | ₹29.32 Bn | ₹29.08 Bn | ₹29.60 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹4.93 Bn | ₹2.07 Bn | ₹3.06 Bn | ₹6.55 Bn | CapitalWorkInProgress |
| Goodwill | ₹0.20 Bn | ₹0.20 Bn | ₹64.93 Bn | ₹64.93 Bn | Goodwill |
| Other Intangible Assets | ₹17.01 Bn | ₹15.88 Bn | ₹96.04 Bn | ₹91.68 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹2.71 Bn | ₹3.10 Bn | ₹1.60 Bn | ₹2.48 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹0.73 Bn | ₹0.66 Bn | ₹0.92 Bn | ₹3.52 Bn | OtherNoncurrentAssets |
| Total Non-current Assets | ₹52.85 Bn | ₹53.13 Bn | ₹205.82 Bn | ₹209.37 Bn | NoncurrentAssets |
| Inventories | ₹14.98 Bn | ₹15.53 Bn | ₹20.94 Bn | ₹21.44 Bn | Inventories |
| Trade Receivables | ₹5.76 Bn | ₹8.48 Bn | ₹15.38 Bn | ₹17.30 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹3.05 Bn | ₹3.82 Bn | ₹4.07 Bn | ₹3.92 Bn | CashAndCashEquivalents |
| Current Investments | ₹10.75 Bn | ₹22.58 Bn | ₹16.91 Bn | ₹15.37 Bn | CurrentInvestments |
| Other Current Assets | ₹6.63 Bn | ₹6.92 Bn | ₹8.03 Bn | ₹8.05 Bn | OtherCurrentAssets |
| Total Current Assets | ₹44.27 Bn | ₹66.48 Bn | ₹71.75 Bn | ₹71.40 Bn | CurrentAssets |
| Total Assets | ₹97.15 Bn | ₹119.63 Bn | ₹277.60 Bn | ₹280.80 Bn | Assets |
| Equity Share Capital | ₹0.40 Bn | ₹0.40 Bn | ₹0.41 Bn | ₹0.41 Bn | EquityShareCapital |
| Other Equity | ₹73.95 Bn | ₹93.23 Bn | ₹142.91 Bn | ₹162.59 Bn | OtherEquity |
| Equity Attributable to Owners | ₹74.35 Bn | ₹93.63 Bn | ₹143.32 Bn | ₹163.00 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹1.88 Bn | ₹2.13 Bn | ₹2.36 Bn | ₹2.61 Bn | NonControllingInterest |
| Total Equity | ₹76.23 Bn | ₹95.76 Bn | ₹145.68 Bn | ₹165.61 Bn | Equity |
| Long-term Borrowings | ₹0.28 Bn | ₹0.33 Bn | ₹55.40 Bn | ₹28.93 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹2.29 Bn | ₹2.68 Bn | ₹75.28 Bn | ₹50.11 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹1.42 Bn | ₹1.75 Bn | ₹29.71 Bn | ₹34.19 Bn | BorrowingsCurrent |
| Trade Payables | ₹10.08 Bn | ₹11.03 Bn | ₹11.33 Bn | ₹13.41 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹1.23 Bn | ₹1.71 Bn | ₹2.03 Bn | ₹1.73 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹18.63 Bn | ₹21.20 Bn | ₹56.64 Bn | ₹65.07 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹97.15 Bn | ₹119.63 Bn | ₹277.60 Bn | ₹280.80 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from MANKIND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).